Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical ...

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...

This Women's History Month, Lume Deodorant founder and lobular breast cancer survivor, Dr. Shannon Klingman, has made a historic $1 million gift to the Lobular Breast Cancer Alliance (LBCA) to fund ...

In addition, the Company announced its management team will attend the 38 th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026. To schedule a one-on-one meeting, ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights. “Over the past year ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...

The Company reported total revenues of $6,715,175 for the year ended December 31, 2025 ("fiscal year 2025”), compared to $6,065,390 for the year ended December 31, 2024 ("fiscal year 2024”). The ...

We finished 2025 with double-digit overall revenue growth in the fourth quarter with continued growth in our Canadian pharmaceutical business and sizable contributions from our international Tibelia ® ...

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and ...

Gross revenue for the fourth quarter of 2025 was €6.3 million before €0.7 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €5.6 million ...

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the year ended ...